| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MYNZ Stock Overview
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.
Mainz Biomed B.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.24 |
| 52 Week High | US$30.00 |
| 52 Week Low | US$7.80 |
| Beta | 0 |
| 1 Month Change | -1.70% |
| 3 Month Change | -22.42% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.51% |
Recent News & Updates
Shareholder Returns
| MYNZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | 1.4% | 3.6% |
| 1Y | n/a | -19.6% | -9.6% |
Return vs Industry: Insufficient data to determine how MYNZ performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MYNZ performed against the US Market.
Price Volatility
| MYNZ volatility | |
|---|---|
| MYNZ Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MYNZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MYNZ's weekly volatility has decreased from 18% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Guido Baechler | https://mainzbiomed.com |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V. Fundamentals Summary
| MYNZ fundamental statistics | |
|---|---|
| Market Cap | US$128.99m |
| Earnings (TTM) | -US$11.69m |
| Revenue (TTM) | US$577.35k |
223.5x
P/S Ratio-11.0x
P/E RatioIs MYNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYNZ income statement (TTM) | |
|---|---|
| Revenue | US$577.35k |
| Cost of Revenue | US$399.73k |
| Gross Profit | US$177.62k |
| Other Expenses | US$11.87m |
| Earnings | -US$11.69m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 30.76% |
| Net Profit Margin | -2,024.79% |
| Debt/Equity Ratio | 33.5% |
How did MYNZ perform over the long term?
See historical performance and comparison